Health
STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
Publication: STAT
Author: Margaret Manto
Source published: 16/11/2026, 18:54:06 UTC
Briefing created: 22/11/2026, 18:59:29 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 13:51:25 UTC.
Briefings
The FDA proposed a new regulatory category for N-acetyl-L-cysteine (NAC), a supplement widely sold over the counter. This move would allow NAC to be classified as a dietary ingredient rather than a drug, resolving a long-standing legal gray area. The proposal stems from the FDA's 1963 approval for lung conditions and 1985 approval for acetaminophen overdose treatment, which previously barred drugs from the supplement category.
Key points
- The FDA proposed classifying N-acetyl-L-cysteine (NAC) as a 'Dietary Ingredient Not Excluded from the Dietary Supplement Definition,' allowing it to be sold as a supplement rather than a drug.
- The proposal resolves a legal gray area where NAC, approved by the FDA in 1963 for lung conditions and in 1985 for acetaminophen overdose, was previously restricted from the dietary supplement category.
Context
The Food and Drug Administration is proposing a new classification for N-acetyl-L-cysteine (NAC), a supplement widely sold over the counter. This move would allow NAC to be classified as a dietary ingredient rather than a drug, resolving a long-standing legal gray area. The proposal stems from the FDA's 1963 approval for lung conditions and 1985 approval for acetaminophen overdose treatment, which previously barred drugs from the supplement category.
Limitations
The evidence is limited to the FDA's proposed rule text and historical approval dates. It does not include public impact data, sales figures, or specific stakeholder reactions. The classification status remains subject to future regulatory review and potential changes.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/11/2026, 18:59:29 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeicekfjycc47stukt7tmncg26xsyphzklbrpovks2q5r7y5lad3gaq